Core Viewpoint - Alps Group Inc successfully completed its business combination with Globalink Investment Inc, marking a significant milestone as it prepares to list on the Nasdaq under the symbol "ALPS" on October 31, 2025 [1][4]. Business Combination Details - The business combination was executed under an Amended and Restated Merger Agreement, with multiple amendments leading up to the final agreement [2]. - The transaction involved a two-step merger process: a Redomestication Merger and an Acquisition Merger, resulting in Alps Group as the surviving publicly traded entity [3]. Trading and Valuation - Following the closing, Alps Group's ordinary shares will begin trading on Nasdaq, with an estimated enterprise value of approximately US$1.6 billion for the combined company [4]. Leadership and Governance - Post-closing, the headquarters of Alps Group will be in Kuala Lumpur, Malaysia, with Dr. Tham Seng Kong serving as the Chief Executive Officer and Chairman of the Board [5]. Strategic Vision - The CEO emphasized the mission to redefine healthcare through predictive, preventive, and precision medicine, aiming to make advanced healthcare accessible globally [6]. - The company plans to develop its BioValley initiative, a biotechnology hub to foster collaboration in the biotech ecosystem [8]. Financial Support - In connection with the business combination, Alps Group secured approximately US$3.1 million from PIPE Investors to support its growth strategy and working capital needs [6].

Core Viewpoint - RetinalGenix Technologies Inc. and RGEN Inc. have formed a strategic partnership aimed at enhancing early detection and risk prediction for neurodegenerative, systemic, and retinal diseases through advanced retinal imaging and DNA genotyping [1][2][4] Group 1: Partnership Objectives and Innovations - The collaboration seeks to integrate advanced retinal imaging with clinical-grade DNA genotyping to develop predictive models for diseases such as Age-Related Macular Degeneration (AMD), Glaucoma, and Alzheimer's Disease [2][4] - This partnership combines RetinalGenix's high-resolution retinal imaging platform with RGEN's CLIA-certified DNA testing capabilities, creating a dual-pronged diagnostic model that captures both retinal changes and DNA variants [3][4] - The integrated approach is expected to improve patient outcomes and reduce healthcare system burdens by enabling earlier intervention and disease management [4] Group 2: Future Steps and Applications - RetinalGenix plans to commercialize a combined screening tool for use in primary care offices, clinics, and remote monitoring locations, as well as to establish partnerships with healthcare payers for preventative care coverage [5] - The partnership aims to expand its platform to address other age-related and neurodegenerative conditions in the future [5] - The collaboration is positioned to redefine the detection and management of chronic and ocular diseases in at-risk populations, paving the way for predictive, preventive, and personalized medicine [5][6] Group 3: Company Backgrounds - RetinalGenix Technologies Inc. focuses on early disease detection and improving patient outcomes through genetic screening and advanced imaging technologies [6] - RGEN Inc. specializes in genetic research and testing, providing genomic solutions that support disease prevention and personalized wellness [7][8]